HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.

AbstractOBJECTIVE:
To assess the effect of pretreatment with an oral contraceptive (OC) on ovarian cyst formation during pituitary suppression with buserelin acetate.
DESIGN:
Prospective randomized trial.
SETTING:
Academic medical center.
PATIENT(S):
Eighty-three patients who were undergoing IVF-ET treatment.
INTERVENTION(S):
Patients in the study group were pretreated with an OC for 14 days starting on the first day of menstruation. The administration of SC buserelin acetate was initiated on the last day of OC administration. Patients in the control group began to receive buserelin acetate on day 2 of menstruation. Hormonal assays and ultrasound scans were performed on the first day of menstruation, and 7, 11, and 14 days after the commencement of buserelin acetate administration. Thereafter, these tests were performed weekly until pituitary suppression was achieved.
MAIN OUTCOME MEASURE(S):
Incidence of cyst formation.
RESULT(S):
A cyst developed in 27 patients in the control group (52.9%) and no patients in the study group (odds ratio [OR]=115; 95% confidence interval [CI]=10-617). Patients in the study group achieved pituitary suppression faster (median difference [MD]=7 days; 95% CI=4-14) and required fewer ampules of gonadotropin (MD=10; 95% CI=6-14). They recruited more follicles (MD=3; 95% CI=0-5) and had higher pregnancy rates (37.2% versus 33.3%).
CONCLUSION(S):
Pretreatment with an OC abolishes ovarian cyst formation, shortens the time required to achieve pituitary suppression, and decreases gonadotropin requirements without having a negative effect on pregnancy rates.
AuthorsM M Biljan, N G Mahutte, N Dean, R Hemmings, F Bissonnette, S L Tan
JournalFertility and sterility (Fertil Steril) Vol. 70 Issue 6 Pg. 1063-9 (Dec 1998) ISSN: 0015-0282 [Print] United States
PMID9848296 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Contraceptives, Oral
  • Gonadotropin-Releasing Hormone
  • Buserelin
Topics
  • Adult
  • Buserelin (therapeutic use)
  • Contraceptives, Oral (therapeutic use)
  • Depression, Chemical
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Embryo Implantation
  • Embryo Transfer
  • Female
  • Fertilization in Vitro
  • Gonadotropin-Releasing Hormone (analogs & derivatives, therapeutic use)
  • Humans
  • Ovarian Cysts (chemically induced, diagnostic imaging, epidemiology)
  • Ovarian Follicle (drug effects)
  • Pituitary Gland (drug effects)
  • Pregnancy
  • Pregnancy Rate
  • Prospective Studies
  • Ultrasonography

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: